【product description】
Selpercatinib is a potent, oral, highly selective rearrangement during transfection (RET) kinase inhibitor for the treatment of cancer patients with abnormal RET.
【Indications】
1. Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); 2. Adult and pediatric patients ≥12 years old with systemic or recurrent RET-mutant medullary thyroid carcinoma (MTC) who require systemic therapy 3. Adult and pediatric patients aged ≥12 years with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and refractory to radioactive iodine (if appropriate, requiring radioactive iodine)
【Dosage】
Recommended dose based on body weight: ① Less than 50kg: 120mg; ② 50kg and above: 160mg. Oral twice daily (approximately every 12 hours) until disease progression or unacceptable toxicity. Swallow the capsule whole without crushing or chewing the capsule shell. Do not miss any dose unless you miss your next scheduled dose by more than 6 hours. If vomiting occurs after taking the medicine, do not take it again, and the next time you take the medicine will still follow the original interval.
商品評價
目前沒有評價。